Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound

This study has been withdrawn prior to enrollment.
(Due to lack of funding and issues with ability to complete all procedures, it was decided that this study could not be carried out and therefore withdrawn.)
Information provided by (Responsible Party):
Glenn Peters, MD, University of Alabama at Birmingham Identifier:
First received: October 14, 2010
Last updated: January 27, 2012
Last verified: January 2012
This study will evaluate thyroid nodules using specialized ultrasound imaging methods.

Condition Intervention
Thyroid Nodules
Drug: Definity contrast agent

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound

Resource links provided by NLM:

Further study details as provided by Glenn Peters, MD, University of Alabama at Birmingham:

Primary Outcome Measures:
  • To estimate the accuracy (sensitivity and specificity) of the contrast enhanced ultrasound for characterization of thyroid nodules. [ Time Frame: 30 days ]

Enrollment: 0
Study Start Date: October 2010
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Definity contrast agent
    Thyroid ultrasound using contrast agent

Ages Eligible for Study:   19 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 1. Patients diagnosed with a thyroid nodule 2. Age greater than or equal to 19 years of age 3. Patients must sign informed consent

Exclusion Criteria:

  • 1. Women who are pregnant or nursing 2. Patients with pulmonary hypertension, unstable cardiopulmonary condition,or right to left shunt 3. Hypersensitivity to perfluten 4. Psychological condition that renders the patient unable to understand the informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01225016

United States, Alabama
Universith of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
Sponsors and Collaborators
University of Alabama at Birmingham
Principal Investigator: Glenn E Peters, MD University of Alabama at Birmingham
  More Information

Responsible Party: Glenn Peters, MD, Professor of Surgery, University of Alabama at Birmingham Identifier: NCT01225016     History of Changes
Other Study ID Numbers: UAB 1007
Study First Received: October 14, 2010
Last Updated: January 27, 2012

Additional relevant MeSH terms:
Thyroid Diseases
Thyroid Nodule
Endocrine System Diseases
Thyroid Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Head and Neck Neoplasms processed this record on May 25, 2017